Key result
Metformin use is linked to slower AAA growth and ~46% fewer AAA-related events.
Why the study?
Studies suggest an inverse correlation between AAA and diabetes, particularly with metformin treatment, but this relationship remains unclear.
Does metformin reduce AAA growth rate and AAA-related events in patients with abdominal aortic aneurysm?
Meta-Analysis (n=148,589)
Does metformin reduce AAA growth rate and AAA-related events in patients with abdominal aortic aneurysm?
Metformin use is associated with a significantly slower growth rate of abdominal aortic aneurysms and a reduction in AAA-related events.
Answers are grounded in this paper and cite their sources.
May support metformin evaluation in AAA; hypothesis-generating from observational data and requires RCT confirmation.
Background Abdominal aortic aneurysm (AAA) is a cardiovascular disease characterized by a high mortality rate when ruptured. Some studies suggest a potential inverse correlation between AAA and diabetes patients, especially those undergoing metformin treatment. However, this relationship remains unclear. This paper offers a systematic review and meta-analysis with the objective of clarifying the influence of metformin on AAA. Methods A search for relevant articles was performed across multiple databases including PubMed, ScienceDirect, Cochrane and Scopus. The focus was on studies that examined the comparative effects of metformin and non-metformin treatments on AAA patients. Data from appropriate studies were consolidated to estimate the effects. Our study encompassed 11 articles, comprising 13 cohorts that compared metformin ( n = 32,250) with a control group ( n = 116,339). Results The random effects meta-analysis revealed that metformin was associated with a slower growth rate (weighted mean difference (WMD) −0.86 mm; 95% CI: −1.21 to −0.52; p < 0.01; I 2 : 81.4%) and fewer AAA-related events (OR: 0.54; 95% CI: 0.34 to 0.86; p = 0.01; I 2 : 60.9%). The findings suggest that metformin may be linked to a reduced risk of aortic aneurysm. A meta-regression analysis indicated that the association between metformin and AAA growth was significantly influenced by male gender ( p = 0.027), but not by age ( p = 0.801), hypertension ( p = 0.256), DM ( p = 0.689), smoking history ( p = 0.786), use of lipid-lowering agents ( p = 0.715), or baseline diameter ( p = 0.291). Conclusion These results hint at a potential role for metformin in limiting annual AAA growth, AAA-related events, and the risk of AAA.
No takes yet. Share an insight, caveat, or question.
Dewangga et al. (2024) conducted a meta-analysis in Abdominal aortic aneurysm (n=148,589). Metformin vs. Non-metformin treatments was evaluated on AAA growth rate (WMD -0.86, 95% CI -1.21 to -0.52, p=<0.01). Metformin use was associated with a slower abdominal aortic aneurysm growth rate and fewer AAA-related events.
Synapse has enriched 10 related papers. Consider them for comparative context: